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Objectives/Hypothesis: To demonstrate that ultrasound-guided fine needle aspiration (USFNA) with on-site cytopatho-
logic analysis eliminates unnecessary diagnostic testing, return visits, and repeat procedures and optimizes quality of care.
Study Design: Retrospective cohort.
Methods: Sixty-one new patients (28 female; 33 male; age range5 19–85 years) were seen in our dedicated neck mass
clinic over a 1-year period. All patients underwent USFNA of masses located in neck levels I–VI (n5 40), parotid gland
(n5 20), or parapharyngeal space (n5 1). Each patient underwent two USFNA passes followed by on-site cytopathologic
analysis with additional passes if required for diagnosis.
Results: Diagnosis was made in 93.4% (n5 57) of patients, allowing for counseling and treatment planning at the first
visit. To obtain a diagnosis, more than half (57.4%, n535) of our patients required additional passes, which implies that
they would have required an additional visit without on-site cytopathologic analysis. Treatment included observation in
42.6% (n5 26) of patients, surgery in 32.8 % (n520) of patients, and nonsurgical treatment (chemotherapy, radiation,
other) in 24.6% (n5 15) of patients. The average time from check-in to checkout including the clinic visit, biopsy, and treat-
ment counseling was 103 minutes, and the average round trip mileage traveled per patient was 127.6 miles.
Conclusions: The adult neck mass is a commonly encountered scenario in otolaryngology. For the patient, this can be a
stressful situation in which timely and accurate diagnosis is critical. A dedicated lean neck mass clinic model with USFNA and
on-site cytopathologic analysis can be both an efficient part of one’s practice and a valuable addition to patient care.
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INTRODUCTION
Early diagnosis and management is critical for suc-
cessful treatment in patients who present with neck
masses as a sequela of malignancy. For patients with
benign disease who present with a neck mass, early
diagnosis can also be very valuable at alleviating con-
cerns and anxiety. As there is no gold standard diagnos-
tic algorithm for these patients, our team orchestrated a
new lean neck mass clinic model with the hope of
improving care for this patient population.
Lean management principles are largely attributed
to Taiichi Ohno and were initially used at Toyota manu-
facturing in Japan. The goal of lean management is to
remove waste from a process so that all remaining work is
value-added while serving a customer’s needs.1,2 Utilizing
lean principles, we describe our dedicated neck mass clinic
and demonstrate that in-office ultrasound-guided fine
needle aspiration (USFNA) with immediate on-site cyto-
pathologic analysis eliminates unnecessary diagnostic
testing, return visits, and repeat procedures and opti-
mizes quality of care.
MATERIALS AND METHODS
This study was performed as a retrospective cohort with
University of Michigan Institutional Review Board approval
(HUM00087331). A total of 117 new patients were seen in our
lean neck mass clinic over a 1-year period. Patients were
excluded if they were given a diagnosis prior to presentation,
had imaging and/or ultrasound characteristics that were diag-
nostic negating need for USFNA, or if they did not undergo
USFNA for other reasons (n548). A total of 61 new patients
(28 female; 33 male; age range519–85) met inclusion criteria.
Patients were not required to hold any medication prior to their
office visit, including anticoagulants. All included patients
underwent a history, head and neck physical examination,
review of any prior imaging, and USFNA of masses of at least
5 mm located in neck levels I–VI (n5 40), parotid gland
(n520), or parapharyngeal space (n51). Each patient under-
went two USFNA passes followed by on-site cytopathologic
analysis. The patients underwent additional passes with repeat
cytopathologic analysis if required with the goal of preliminary
diagnosis at the same visit. On-site core needle biopsy was per-
formed if there was concern for lymphoma based on history and
physical, particularly if the patient complained of B symptoms,
or if the cytopathologist requested additional tissue to make a
diagnosis and/or treatment plan based on fine needle aspiration
(FNA; n5 6).
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All office-based USFNA procedures were performed by one
staff otolaryngologist with expertise in head and neck oncology as
well as American College of Surgeons Thyroid and Parathyroid
Ultrasound certification. Ultrasound was performed with Doppler
as appropriate to further delineate any vascular involvement.
The lesions were visualized on ultrasound and marked appropri-
ately, and then local anesthetic (1% lidocaine with 1/100,00 epi-
nephrine) was injected into the presumed FNA trajectory. Next, a
22-gauge needle was used to aspirate the mass under ultrasound
guidance and the mass was documented. Two passes were per-
formed (Fig. 1). The specimens were then immediately handed off
to the on-site cytopathologist or cytotechnician for immediate
Fig. 1. (A) Examination room setup for a right-sided neck mass. Note that sharp instruments are out of patient sight, which may help ease anxi-
ety. The patient is asked to visualize the ultrasound screen, which assists with access. (B) After ultrasound examination, the expected trajectory
is marked and local anesthetic is injected. (C) A 22-gauge needle is used to perform the fine needle aspiration with negative pressure. (D) The
needle is visualized under ultrasound guidance and multiple micropasses are made within the mass to improve diagnostic yield before releasing
the plunger and withdrawing the needle. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
Fig. 2. How a diagnosis was obtained for the
61 patients who visited our neck mass clinic.
Diagnosis was made in 93.4% (n557) of
patients at their first visit; more than half
(57.4%, n5 35) of these patients required
additional passes, which implies that they
would have required an additional visit without
on-site cytopathologic analysis. Of the four
patients who did not receive a diagnosis after
the first visit, two obtained a diagnosis after
additional studies, and no diagnosis was
made in the other two. [Color figure can be
viewed in the online issue, which is available
at www.laryngoscope.com.]
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TABLE I.
Breakdown of Patient Characteristics, Clinic Findings, and Outcomes.
Age, yr Sex Location
Additional
Passes?
Diagnosis at
First Visit? Diagnosis Outcome
81 F Parotid Y Y Warthin tumor Observation
68 M Level IV Y N None (reactive lymphadenopathy) Observation
48 M Level II N Y Benign salivary gland tissue Observation
53 M Level II Y Y Squamous cell carcinoma Nonsurgical treatment
28 F Anterior neck N Y Thyroglossal duct cyst Observation
24 F Level I N Y Reactive lymphadenopathy Observation
61 F Level I N Y Sialocele Observation
24 M Level V Y Y Lymphoma Nonsurgical treatment
66 F Level I Y Y Reactive lymphadenopathy Observation
56 M Level I Y Y Reactive lymphadenopathy Observation
77 M Level II–IV
bilateral
N Y Lymphoma Nonsurgical treatment
39 F Level II–IV N Y Pleomorphic adenoma Surgical treatment
63 M Level II N Y Squamous cell carcinoma Surgical treatment
80 M Level II Y Y Merkel cell carcinoma Surgical treatment
89 M Levels I–V Y Y Lymphoma Nonsurgical treatment
57 M Level II Y Y Squamous cell carcinoma Surgical treatment
63 M Level II Y Y Poorly differentiated carcinoma Nonsurgical treatment
51 M Levels I–V Y Y Infection/tuberculosis Nonsurgical treatment
59 F Level VI Y Y Nodular hyperplasia Observation
63 M Parotid Y Y Squamous cell carcinoma Surgical treatment
70 M Level I Y N None (sialadenitis) Further workup,
nonsurgical treatment
39 M Parotid N Y Simple cyst Surgical treatment
94 F Parotid N Y Low-grade oncocytic neoplasm Observation
68 F Level I Y Y Reactive lymphadenopathy Observation
72 F Parotid N Y Pleomorphic adenoma Surgical treatment
30 F Parotid Y Y Parotid cyst Surgical treatment
59 M Level II N Y Squamous cell carcinoma Nonsurgical treatment
70 M Parotid N Y Parotid cyst Observation
25 M Level V N Y Reactive lymphadenopathy Observation
69 F Level II Y Y Squamous cell carcinoma Nonsurgical treatment
66 F Level V N Y Reactive lymphadenopathy Observation
66 F Parotid Y Y Warthin tumor Surgical treatment
44 F Level I Y Y Reactive lymphadenopathy Observation
50 M Parapharyngeal Y N None (paraganglioma) Further workup, observation
47 M Parotid N Y Pleomorphic adenoma Surgical treatment
77 M Parotid Y Y Granulation Observation
65 M Parotid N Y Warthin tumor Observation
77 F Level II N Y Warthin tumor Observation
30 M Parotid Y Y Pleomorphic adenoma Surgical treatment
67 F Level I Y Y Low-grade malignancy Surgical treatment
67 F Level II Y Y Venous malformation Observation
53 M Level II Y Y Squamous cell carcinoma Nonsurgical treatment
66 M Level III Y Y Paraganglioma Observation
60 F Parotid Y Y Low-grade neoplasm Surgical treatment
20 F Level II Y Y Reactive lymphadenopathy Observation
47 M Level II–IV Y Y Squamous cell carcinoma Nonsurgical treatment
64 M Parotid N Y Warthin tumor Nonsurgical treatment
63 M Level V Y Y Pleomorphic lipoma Surgical treatment
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processing and reviewed in person or via telecommunication with
an off-site cytopathologist. Repeat passes were performed if the
specimen was inadequate as necessary. The cytopathologist
reported their preliminary diagnosis to the surgeon to be shared
with the patient followed by counseling and planning if
appropriate.
RESULTS
Diagnosis was made in 93.4% (n5 57) of patients,
allowing for counseling and treatment planning at the
first visit (Fig. 2). To obtain a diagnosis, more than half
(57.4%, n5 35) of our patients required additional
passes, which implies that they would have required an
additional visit without on-site cytopathologic analysis.
On-site core needle biopsy was performed in 8.7% (n5 6)
of patients if lymphoma was highest on the differential
diagnosis or if additional tissue was required for diagno-
sis and/or treatment planning. All patients with a
parotid mass received a diagnosis at the first visit. Of
the four patients who did not receive a diagnosis at the
first visit and required additional workup, three had
neck masses (n5 2 level I, n5 1 level IV) and one had a
parapharyngeal space mass.
The average time from check-in to checkout includ-
ing the clinic visit, biopsy, and treatment counseling was
103 minutes. The average round trip mileage traveled
per patient was 127.6 miles. Treatment included obser-
vation in 47.5% (n5 29) of patients, surgery in 31.1%
(n5 19) of patients, and nonsurgical treatment (chemo-
therapy6 radiation) in 21.3% (n5 13) of patients (Table I).
There were no major complications reported in any
patient, including infection, hematoma, or neuropathy.
Of the 19 patients who had surgical therapy, 16
patients had their diagnosis confirmed on final pathol-
ogy. The other three patients all had low-grade salivary
gland neoplasms on their USFNA. After surgical exci-
sion, these were further stratified as an oncocytoma
(n51), basal cell adenoma (n5 1), and low-grade mucoe-
pidermoid carcinoma (n5 1).
DISCUSSION
Our clinical model provides a standardized algo-
rithm that promotes expedient diagnosis, counseling,
and formation of a treatment plan. By reducing time to
diagnosis and the need for return visits, this model
decreases wait times for new referrals and allows the
surgeon to see more new patients. Additionally, office-
based ultrasound and ultrasound-guided procedures
have been proven to be a cost-effective tool for the head
and neck surgeon.3 In-office USFNA often avoids the
need for further imaging for diagnosis or alternatively,
guides further imaging for treatment planning if needed.
Although USFNA has a higher sensitivity and speci-
ficity when compared to conventional FNA with palpation
alone, it historically fails to provide an adequate sample
or has indeterminate cytologic findings in 10% to 20% of
cases.4,5 On-site cytopathologic review can immediately
assess the adequacy of a specimen and improve diagnostic
yield. A study by Moberly et al. compared methods of
review for USFNA and found that the diagnostic rate
was increased and the rate of adequate specimens
obtained showed a positive trend when a cytopathologist
was present at the time of biopsy.6 With immediate cyto-
logic analysis, the surgeon has the ability to communicate
with the cytopathologist regarding differential diagnosis
and concerns based on history, physical, and ultrasound
characteristics that may also enhance diagnostic yield.
The patient benefits most greatly from this practice
model. Prior to the opening of this clinic, a patient pre-
senting with a neck mass would be referred to any avail-
able new head and neck patient slot with any number of
otolaryngology providers. Their workup from that point
would be entirely provider specific and may have included
history and physical only, further radiologic imaging,
TABLE I.
(Continued)
Age, yr Sex Location
Additional
Passes?
Diagnosis at
First Visit? Diagnosis Outcome
67 M Parotid N Y Low-grade neoplasm Observation
67 F Parotid N Y Low-grade neoplasm Surgical treatment
50 M Level V N Y Simple cyst Observation
85 F Parotid bilateral N Y Warthin tumor Observation
29 M Level II N Y Branchial cleft cyst Surgical treatment
19 M Level I Y N None (schwannoma) Further workup,
surgical treatment
51 F Parotid N Y Pleomorphic adenoma Surgical treatment
52 F Parotid Y Y Warthin tumor Observation
63 F Level V Y Y Lymphoma Nonsurgical treatment
33 M Level V Y Y Lymphoma Nonsurgical treatment
41 F Level VI N Y Papillary thyroid carcinoma Surgical treatment
29 F Parotid N Y Pleomorphic adenoma Surgical treatment
58 F Level II–IV bilateral Y Y Noncaseating granuloma Nonsurgical treatment
F5 female; M5male.
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pathology- or radiology-performed FNA, physician-performed
FNA, or physician-performed USFNA without on-site
cytopathologic analysis. Patients almost always required
at least two to three visits for diagnosis and counseling.
Some providers also routinely performed operative exci-
sional biopsy after a nondiagnostic FNA.
Patients specifically benefit from reduced time to
diagnosis, as most patients are given a preliminary diag-
nosis on the day of their first visit. There is improved
diagnostic accuracy with USFNA with on-site cytopathol-
ogy, which decreases the need for repeat procedures and
leads to decreased patient discomfort overall. There is
reduced risk to the patient in our model for several rea-
sons. First, they avoid radiation from additional imaging.
Second, they avoid the anesthetic risk from an excisional
biopsy. Third, because we do not require the patient to
hold anticoagulation for USFNA, their risk of thromboem-
bolic events is reduced. Lastly, because cytotechnicians
can immediately assess the quality of an FNA sample,
repeat passes do not require additional anesthetic, and
patients have reported less pain than with traditional
FNA. Patients incur less cost, as this model requires
fewer trips to our facility for which they must pay for
transportation, meals, and parking, and have a reduced
need for radiologic studies and diagnostic operative inter-
vention, both of which can cost a patient thousands of
dollars. Patients benefit emotionally, as they are rarely
left waiting for a diagnosis, leading to less anxiety in the
weeks between office visits. They also are provided with
counseling at their first visit, which either provides them
with reassurance or assists them in early planning.
CONCLUSION
The adult neck mass is a commonly encountered
scenario in otolaryngology. For the patient, this can be a
stressful situation in which timely and accurate diagno-
sis is critical. A dedicated lean neck mass clinic model
with USFNA and on-site cytopathologic analysis can be
both an efficient part of one’s practice and a valuable
addition to patient care.
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